ES490944A0 - Un metodo para la preparacion de un anticuerpo monoclonico, de fijacion de complemento - Google Patents

Un metodo para la preparacion de un anticuerpo monoclonico, de fijacion de complemento

Info

Publication number
ES490944A0
ES490944A0 ES490944A ES490944A ES490944A0 ES 490944 A0 ES490944 A0 ES 490944A0 ES 490944 A ES490944 A ES 490944A ES 490944 A ES490944 A ES 490944A ES 490944 A0 ES490944 A0 ES 490944A0
Authority
ES
Spain
Prior art keywords
complement
fixation
preparation
monoclonal antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES490944A
Other languages
English (en)
Spanish (es)
Other versions
ES8105152A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21871750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES490944(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Publication of ES8105152A1 publication Critical patent/ES8105152A1/es
Publication of ES490944A0 publication Critical patent/ES490944A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES490944A 1979-04-26 1980-04-25 Un metodo para la preparacion de un anticuerpo monoclonico, de fijacion de complemento Granted ES490944A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/033,669 US4361549A (en) 1979-04-26 1979-04-26 Complement-fixing monoclonal antibody to human T cells, and methods of preparing same

Publications (2)

Publication Number Publication Date
ES8105152A1 ES8105152A1 (es) 1981-05-16
ES490944A0 true ES490944A0 (es) 1981-05-16

Family

ID=21871750

Family Applications (1)

Application Number Title Priority Date Filing Date
ES490944A Granted ES490944A0 (es) 1979-04-26 1980-04-25 Un metodo para la preparacion de un anticuerpo monoclonico, de fijacion de complemento

Country Status (22)

Country Link
US (1) US4361549A (enExample)
EP (1) EP0018795B2 (enExample)
JP (2) JPS55145617A (enExample)
AT (1) ATE14023T1 (enExample)
AU (1) AU544791B2 (enExample)
CA (1) CA1182406A (enExample)
DE (2) DE18795T1 (enExample)
DK (1) DK154769C (enExample)
ES (1) ES490944A0 (enExample)
FI (1) FI75183C (enExample)
HK (1) HK23886A (enExample)
IE (1) IE50422B1 (enExample)
IL (1) IL59917A (enExample)
MY (1) MY8600514A (enExample)
NL (1) NL930131I2 (enExample)
NO (1) NO159221C (enExample)
NZ (1) NZ193469A (enExample)
PH (1) PH16642A (enExample)
PT (1) PT71147B (enExample)
SG (1) SG6686G (enExample)
YU (1) YU48442B (enExample)
ZA (1) ZA802525B (enExample)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582797A (en) * 1980-09-25 1986-04-15 The Salk Institute For Biological Studies Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
DE3105150A1 (de) * 1981-02-12 1982-08-19 Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg Herstellung von anti-t-lymphozyten-globulin.
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4471056A (en) * 1982-04-02 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for HLA-DR typing of total human lymphocyte sample
US4657852A (en) * 1982-04-02 1987-04-14 The Board Of Trustees Of The Leland Stanford Junior University Method for B cell typing of total human lymphocyte sample
US4511662A (en) * 1982-06-18 1985-04-16 Bio-Rad Laboratories, Inc. Simultaneous assay for T and B lymphocyte populations and subpopulations
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
US4714613A (en) * 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4797475A (en) * 1983-05-20 1989-01-10 The Regents Of The University Of California Method and composition for isolating white cell elements
US4645738A (en) * 1983-09-30 1987-02-24 Memorial Sloan-Kettering Institute Cancer Center Method for differential diagnosis of T cell leukemias using monoclonal antibodies
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
JPS60231699A (ja) * 1983-11-09 1985-11-18 Aichiken 正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US4661446A (en) * 1985-02-19 1987-04-28 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies and method of immunizing therewith
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4970299A (en) * 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
AU622137B2 (en) * 1987-10-16 1992-04-02 Biomedical Systems Limited Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
JPH0291833U (enExample) * 1988-12-29 1990-07-20
JPH0277212U (enExample) * 1989-01-25 1990-06-13
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
EP0497883B1 (en) * 1989-10-27 1998-07-15 Arch Development Corporation Compositions and their use for promoting immunopotentiation
JPH0420550U (enExample) * 1990-06-11 1992-02-20
US5444155A (en) * 1991-09-10 1995-08-22 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US5250426A (en) * 1991-10-22 1993-10-05 The Scripps Research Institute Molecules with antibody combining sites that induce asymmetry
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
RU2160313C2 (ru) * 1993-09-03 2000-12-10 Чугаи Сейяку Кабусики Кайса Моноклональное антитело, реагирующее с поверхностным агентом стромальных клеток и продуцирующая его гибридома
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
JP2000503003A (ja) 1995-12-22 2000-03-14 イムノメディクス，インコーポレイテッド 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
ATE424410T1 (de) 1996-08-30 2009-03-15 Human Genome Sciences Inc Interleukin-19.
AU1539699A (en) * 1997-11-24 1999-06-15 Johnson T. Wong Methods for treatment of hiv or other infections using a t cell or viral activator and anti-retroviral combination therapy
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US8557868B2 (en) * 2000-11-04 2013-10-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions using low molecular weight amines
US9492582B2 (en) * 2000-11-08 2016-11-15 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US20070110782A1 (en) * 2000-11-08 2007-05-17 Fxs Ventures, Llc L-histidine in ophthalmic solutions
US20060148665A1 (en) * 2000-11-08 2006-07-06 Bioconcept Laboratories Ophthalmic and contact lens solutions containing forms of vitamin b
JP4084997B2 (ja) * 2000-11-08 2008-04-30 エフエックスエス・ベンチャーズ・エルエルシー 防腐剤増強剤として単純糖類を含有する改良眼科用およびコンタクトレンズ用溶液
US20070104744A1 (en) * 2000-11-08 2007-05-10 Fxs Ventures, Llc Ophthalmic and contact lens solutions containing forms of vitamin b
DK1339414T3 (da) * 2000-11-08 2010-04-19 Fxs Ventures Llc L-histidin i ophthalmiske opløsninger
US9308264B2 (en) 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US20060127496A1 (en) * 2000-11-08 2006-06-15 Bioconcept Laboratories L-histidine in ophthalmic solutions
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
US7939501B2 (en) * 2003-04-15 2011-05-10 Smith Francis X Ophthalmic and contact lens solutions containing peptides as preservative
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
JP5027512B2 (ja) 2003-11-14 2012-09-19 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫調節法
SG10201504917PA (en) * 2005-07-11 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
BRPI0721062A2 (pt) * 2006-12-21 2019-09-24 Macrogenics Inc métodos para prevenir ou retardar o início e para prevenir a progressão de diabete autoimune latente, métodos para tratamento de diabete autoimune latente em adultos e para tratar ou prevenir diabete de tipo 1 de início na idade adulta ou para melhorar seus sintomas em um paciente sofrendo do mesmo, e, método para prevenir ou retardar requisição de insulina em um paciente.
SG10201700096VA (en) 2009-07-17 2017-02-27 Bioatla Llc Simultaneous, Integrated Selection And Evolution Of Antibody/Protein Performance And Expression In Production Hosts
AU2011246893A1 (en) 2010-04-29 2012-11-08 Hadasit Medical Research Service And Development Co. Ltd. Methods and compositions for treating hepatitis with anti-CD3 immune molecule therapy
EP3435087B1 (en) 2010-07-16 2023-11-08 BioAtla, Inc. Novel methods of protein evolution
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
CN105924519B (zh) 2010-12-31 2019-08-23 生物蛋白有限公司 全面单克隆抗体产生
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
EP2817625B1 (en) 2012-02-23 2025-01-01 Juno Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
DK2847231T3 (da) 2012-05-10 2019-10-14 Bioatla Llc Multispecifikke monoklonale antistoffer
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US11293929B2 (en) 2014-01-07 2022-04-05 Bioatla, Inc. Proteins targeting orthologs
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SMT202100600T1 (it) 2014-04-16 2021-11-12 Juno Therapeutics Gmbh Metodi, kit e apparecchiatura per espandere una popolazione di cellule
EP4219687B1 (en) 2014-04-23 2024-08-14 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
NZ734803A (en) 2015-01-23 2023-03-31 Sanofi Sa Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3411407B1 (en) 2016-02-05 2024-04-03 Orionis Biosciences BV Bispecific signaling agents and uses thereof
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3060526A1 (en) 2017-04-27 2018-11-01 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
AU2019374790A1 (en) 2018-11-06 2021-05-27 Juno Therapeutics, Inc. Process for producing genetically engineered T cells
WO2021064069A1 (en) 2019-10-02 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of adult t-cell leukemia/lymphoma
EP4051402A1 (en) 2019-10-30 2022-09-07 Juno Therapeutics GmbH Cell selection and/or stimulation devices and methods of use
CA3169672A1 (en) 2020-02-12 2021-08-19 Juno Therapeutics, Inc. Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
US20230087953A1 (en) 2020-02-12 2023-03-23 Juno Therapeutics, Inc. Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
CN115697403A (zh) 2020-03-10 2023-02-03 迪赞纳生命科学公开有限公司 Il-6/il-6r抗体的组合物及其使用方法
EP4150057A2 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
AU2021291029A1 (en) 2020-06-17 2022-11-03 Tiziana Life Sciences Plc Compositions and methods for augmenting chimeric antigen receptor (CAR) T cell therapies
IL299744A (en) 2020-07-30 2023-03-01 Tiziana Life Sciences Plc Antibodies to CD-3 for the treatment of the corona virus
EP4323404A1 (en) 2021-04-16 2024-02-21 Tiziana Life Sciences PLC Subcutaneous administration of antibodies for the treatment of disease
US20250283037A1 (en) 2021-05-06 2025-09-11 Juno Therapeutics Gmbh Methods for stimulating and transducing t cells
JP2024538064A (ja) 2021-10-14 2024-10-18 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー ミクログリア活性化を抑制するための方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023147331A1 (en) 2022-01-26 2023-08-03 Mabswitch Inc. Bispecific molecule with tunable affinity to a targetted antigen
WO2023147510A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Chromatography arrays and related methods and kits
WO2023150518A1 (en) 2022-02-01 2023-08-10 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4532695A1 (en) 2022-05-25 2025-04-09 Celgene Corporation Methods of manufacturing t cell therapies
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4630782A1 (en) 2022-12-09 2025-10-15 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
AU2024214593A1 (en) 2023-02-03 2025-08-07 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
TW202502363A (zh) 2023-02-28 2025-01-16 美商奇諾治療有限公司 用於治療全身性自體免疫疾病之細胞療法
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025049250A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 6,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049254A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Pyrazolopyridine based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025049253A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. Bridged cycle‑based inhibitors of dna‑dependent protein kinase and compositions and application in gene editing
WO2025049247A1 (en) 2023-08-25 2025-03-06 Juno Therapeutics, Inc. 5,6-core silacycle based inhibitors of dna-dependent protein kinase and compositions and application in gene editing
WO2025083196A1 (en) 2023-10-18 2025-04-24 Tq Therapeutics Gmbh A method of manufacturing a cellular therapy product and respective kits and devices
US20250241912A1 (en) 2024-01-25 2025-07-31 Juno Therapeutics, Inc. Use of bridged cycle-based inhibitors of dna-dependent protein kinase in combination of dna polymerase theta inhibitor and compositions and application in gene editing
WO2025179188A1 (en) 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR956062A (enExample) * 1950-01-24
GB824492A (en) * 1955-10-07 1959-12-02 Frederick William Beinlich Process and apparatus for the generation of power
US3988895A (en) * 1974-01-11 1976-11-02 Itzhak Sheinbaum Power generation from hot brines
US3986362A (en) * 1975-06-13 1976-10-19 Petru Baciu Geothermal power plant with intermediate superheating and simultaneous generation of thermal and electrical energy
US4089175A (en) * 1975-06-23 1978-05-16 Occidental Petroleum Corporation Process and system for recovery of energy from geothermal brines and other water containing sources by direct contact with a working fluid below the critical pressure
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
BE875277A (fr) * 1979-04-02 1979-10-02 Jourdain Leon J Machine motrice
US4284412A (en) * 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses

Also Published As

Publication number Publication date
EP0018795B2 (en) 1999-04-07
FI801342A7 (fi) 1980-10-27
AU5775780A (en) 1980-10-30
EP0018795B1 (en) 1985-06-26
FI75183B (fi) 1988-01-29
EP0018795A2 (en) 1980-11-12
NL930131I2 (nl) 1998-07-01
MY8600514A (en) 1986-12-31
PT71147B (en) 1981-08-11
DK180380A (da) 1980-10-27
IE50422B1 (en) 1986-04-16
NZ193469A (en) 1984-07-06
JPH0198478A (ja) 1989-04-17
JPS55145617A (en) 1980-11-13
DK154769C (da) 1989-06-19
DE3070803D1 (en) 1985-08-01
US4361549A (en) 1982-11-30
PT71147A (en) 1980-05-01
IL59917A0 (en) 1980-06-30
ES8105152A1 (es) 1981-05-16
YU48442B (sh) 1998-07-10
ATE14023T1 (de) 1985-07-15
DK154769B (da) 1988-12-19
NO159221C (no) 1988-12-07
NL930131I1 (nl) 1993-11-01
JPS6362520B2 (enExample) 1988-12-02
IE800840L (en) 1980-10-24
JPH0159868B2 (enExample) 1989-12-20
PH16642A (en) 1983-12-06
EP0018795A3 (en) 1981-01-07
SG6686G (en) 1986-08-01
HK23886A (en) 1986-04-11
AU544791B2 (en) 1985-06-13
NO159221B (no) 1988-08-29
IL59917A (en) 1983-12-30
DE18795T1 (de) 1984-07-19
CA1182406A (en) 1985-02-12
YU114680A (en) 1984-02-29
NO801214L (no) 1980-10-27
ZA802525B (en) 1981-12-30
FI75183C (fi) 1988-05-09

Similar Documents

Publication Publication Date Title
ES490944A0 (es) Un metodo para la preparacion de un anticuerpo monoclonico, de fijacion de complemento
ES497425A0 (es) Un metodo de preparacion de un anticuerpo monoclonal.
ES490943A0 (es) Un metodo para la preparacion de un anticuerpo monoclonico.
ES489757A0 (es) Un metodo para la preparacion de un anticuerpo monoclonico.
NO159885C (no) Monoklonalt antistoff.
ES497424A0 (es) Un metodo de preparacion de un anticuerpo monoclonal.
ES497423A0 (es) Un anticuerpo monoclonico